Ophthalmic Mutual Insurance Company Acknowledges FDA-Approved Status of Mitosol
The Ophthalmic Mutual Insurance Company (OMIC) has revised its consent forms related to glaucoma filtering surgery to acknowledge the exclusive FDA-approved status of Mobius Therapeutics’ Mitosol (mitomycin for solution) Kit for ophthalmic use in glaucoma filtering surgery, according to a news release.
“This is an important step in ensuring patient and physician awareness of the FDA-approved status of critical medications,” Ed Timm, president and CEO of Mobius Therapeutics, said in a news release. “In the past, physicians did not have a choice with respect to antimetabolites, requiring consent for the off-label use of a highly potent substance. With the approved status of Mitosol now communicated clearly to the patient, both the patient and surgeon can avoid the inherent risks of compounding pharmacies and compounded sterile medications.”
OMIC is a member-owned mutual insurance company sponsored by the American Academy of Ophthalmology. “Mobius applauds the foresight of OMIC in communicating this policy to their insured and their patients,” Mr. Timm said.